Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1965 1
1966 5
1967 2
1969 1
1972 3
1973 3
1974 2
1975 2
1976 1
1977 1
1978 2
1979 3
1982 4
1983 8
1984 12
1985 5
1986 7
1987 14
1988 19
1989 14
1990 14
1991 21
1992 11
1993 18
1994 4
1995 14
1996 6
1997 3
1998 6
1999 11
2000 9
2001 6
2002 7
2003 12
2004 6
2005 8
2006 11
2007 12
2008 12
2009 10
2010 18
2011 9
2012 9
2013 17
2014 30
2015 14
2016 19
2017 35
2018 57
2019 48
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

526 results
Results by year
Filters applied: . Clear all
Page 1
Adverse Effects of Immunoglobulin Therapy.
Guo Y, Tian X, Wang X, Xiao Z. Guo Y, et al. Front Immunol. 2018 Jun 8;9:1299. doi: 10.3389/fimmu.2018.01299. eCollection 2018. Front Immunol. 2018. PMID: 29951056 Free PMC article. Review.
Chimeric Antigen Receptor Therapy.
June CH, Sadelain M. June CH, et al. N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169. N Engl J Med. 2018. PMID: 29972754 Review. No abstract available.
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Neelapu SS, et al. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Nat Rev Clin Oncol. 2018. PMID: 28925994 Free PMC article. Review.
Engineering Natural Killer Cells for Cancer Immunotherapy.
Rezvani K, Rouce R, Liu E, Shpall E. Rezvani K, et al. Mol Ther. 2017 Aug 2;25(8):1769-1781. doi: 10.1016/j.ymthe.2017.06.012. Epub 2017 Jun 28. Mol Ther. 2017. PMID: 28668320 Free PMC article. Review.
CAR T-cell therapy: Full speed ahead.
Sermer D, Brentjens R. Sermer D, et al. Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591. Hematol Oncol. 2019. PMID: 31187533 Review.
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Raje N, et al. N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226. N Engl J Med. 2019. PMID: 31042825 Clinical Trial.
Managing the toxicities of CAR T-cell therapy.
Neelapu SS. Neelapu SS. Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595. Hematol Oncol. 2019. PMID: 31187535 Review.
526 results
Jump to page
Feedback